Back to search results

Genicular Artery Embolization for Knee Osteoarthritis

This study is testing if a procedure called genicular artery embolization (GAE) can effectively treat knee pain caused by osteoarthritis. Osteoarthritis pain can be linked to inflammation and increased blood flow in the knee. GAE uses tiny Embozene MicroSpheres, which are injected into the artery in your knee that goes to the painful area. This aims to reduce blood flow, decrease inflammation, and control pain. You might be able to join if you are between 40 and 79 years old, have moderate to severe knee pain from osteoarthritis, and are not able to have or have refused surgery. The study will measure changes in your clinical response to see if the treatment is successful. The current status of the study is unclear.

Study design
This is a single-center, prospective, open-label randomized trial comparing GAE to observation. It plans to enroll 100 participants.
What's involved
You would be followed for 24 months. After screening, you would be randomly assigned to either receive GAE or be in an observation group.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 24 months after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04682652

Genicular Artery Embolization Vs Observation for Symptomatic Knee Osteoarthritis

Active, Not Recruiting
NAAges 40–79InterventionalTreatment
University of California, Los Angeles
~100 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:Embozene MicroSpheres

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in clinical response
Measured over 6 months

Conditions

Knee Osteoarthritis
Degenerative Joint Disease of Knee

Explore related trials

Osteoarthritis of knee

NCT04682652

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UCLA Santa Monica Hospital

    Santa Monica, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Siddharth A Padia, MD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provided informed consent
Age ≥ 40 years and less than 80 years
Ineligibility for or refusal of surgical management
Moderate-severe knee pain as determined by visual analog scale \> 5 out of 10
Osteoarthritis based on X-ray. Kellgren-Lawrence score \> 2 based on radiograph completed within 3 months of procedure date.
Resistant/failed conservative treatment (e.g. NSAIDS/physical therapy/steroid joint injection/ hyaluronic acid joint injection) for at least 3 months
Able to comply with all treatments and protocol follow-up visits

Exclusion

Mild knee pain as determined by visual analog scale \< 5 out of 10
OA on knee radiograph resulting in greater than 20 degree varus or valgus angulation
Moderate loss of kidney function, define as estimated glomerular filtration rate of less than 45 mL/min.
Significant arterial atherosclerosis that would limit selective angiography
History of fibromyalgia, autoimmune, or inflammatory disorder
History of any lumbar spine surgery, spine injections, or radicular pain in the extremity believed to originate from the spine
Allergy to iodinated contrast agents
Active Infection or malignancy
Recent (within 12 months) or active nicotine use
Prior total or partial knee replacement in the subject knee
Active pregnancy
Uncorrectable bleeding diasthesis
Other medical, social, or psychological/physical conditions that, in the opinion of the investigator, preclude the patient from participating in the study.

What this trial measures

  • Changes in clinical response6 months

    The primary evaluation is the change in clinical response, measured by The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The primary endpoint is percentage of subjects achieving at least a 50% reduction in WOMAC at 6 months with an intent-to-treat analysis.